Silexion Shows Promising Preclinical Results in Cancer Studies
Silexion Therapeutics (NASDAQ: SLXN) has completed preclinical studies of its RNAi therapeutic candidate, SIL204, in colorectal, lung, and pancreatic...
Risvodetinib for Parkinson’s: End of Phase 2 FDA Meeting Details Announced
ABLi Therapeutics recently completed an End of Phase 2 meeting with the FDA to discuss results from their Parkinson’s...
Summit Max Trial Shows Highest First Pass Effect in Stroke Thrombectomy
Route 92 Medical announced positive results from its SUMMIT MAX trial of the HiPoint Reperfusion System, including the super-bore...
Microglia-Driven Inflammation: Key to Parkinson’s and Alzheimer’s?
ZyVersa Therapeutics announced new research supporting the potential of its Inflammasome ASC Inhibitor IC 100 as a disease-modifying treatment...
Galimedix Publishes Groundbreaking Alzheimer’s Data
Galimedix Therapeutics announced published preclinical data on GAL-201, a small molecule drug candidate for Alzheimer’s disease. The data demonstrates...
Tango Tx Doses First Patient in TNG456 Glioblastoma Trial
Tango Therapeutics has initiated a Phase 1/2 clinical trial of TNG456, a brain-penetrant PRMT5 inhibitor, for patients with MTAP-deleted...
Tonix Doses First Patient in Phase 2 OASIS Study of TNX-102 SL
Tonix Pharmaceuticals has initiated a Phase 2 trial, called OASIS, to evaluate TNX-102 SL for reducing the severity of...
Scaling GenAI in Life Sciences: Overcoming Barriers with Strategy, Compliance, and Human Insight
As GenAI gains traction across life sciences, the conversation is rapidly shifting from potential to practicality. Yet, many organizations...
Transforming Clinical Trials: Anca Copaescu on Clinical Trial Business Infrastructure, AI, and Vendor Management
In this interview, Anca Copaescu, Founder and CEO at Strategikon, explores the complexities of clinical trial management. Anca provides...
Regeneron Acquires 23andMe in Court-Supervised Sale
23andMe, a consumer genetics and biotechnology company, has entered into a definitive agreement to be acquired by Regeneron Pharmaceuticals...